EGFR and non-small cell lung carcinoma: The “classical” EGFR mutations, such as the L858R point mutation in exon 21 and the in-frame deletional mutation in exon 19, have been undoubtedly associated with target therapy response, while many other EGFR mutations are rarely detected in patients with NSCLC, and information about their association with response to target therapy are still uncertain (6).